地舒单抗治疗骨巨细胞瘤的卫生技术评估(7)
[23] RUTKOWSKI P，FERRARI S，GRIMER RJ，et al. Surgical downstaging in an open-label phase Ⅱ trial of denosumab in patients with giant cell tumor of bone[J]. Ann Surg Oncol，2015，22(9)：2860-2868.
[24] BRANSTETTER DG，NELSON SD，MANIVEL JC，et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone[J]. Clin Cancer Res，2012，18(16)：4415-4424.
[25] CAMPANACCI L，SAMBRI A，MEDELLIN MR，et al. A new computerized tomography classification to evaluate response to Denosumab in giant cell tumors in the extremities[J]. Acta Orthop Traumato，2019，53(5)：376-380.
[26] RUTKOWSKI P，GASTON L，BORKOWSKA A，et al. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone-multicenter analysis outside clinical trial[J]. EJSO，2018，44(9)：1384-1390.
[27] ZOU C，LIN T，WANG B，et al. Managements of giant cell tumor within the distal radius：a retrospective study of 58 cases from a single center[J]. J Bone Oncol，2019. DOI：10.1016/j.jbo.2018.100211.
[28] 國家药品监督管理局药品审评中心.地舒单抗注射液申请上市技术评审报告[R]. 2019-10.
[29] BIERMANN JS，CHOW W，REED DR，et al. NCCN guidelines insights：bone cancer，version 2：2017[J]. J Natl Compr Canc Netw，2017. DOI：10.6004/jnccn.2017.0017.
(收稿日期：2020-04-29 修回日期：2020-06-18)
(编辑：孙 冰), http://www.100md.com(芮明军 唐文熙 李洪超)
[24] BRANSTETTER DG，NELSON SD，MANIVEL JC，et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone[J]. Clin Cancer Res，2012，18(16)：4415-4424.
[25] CAMPANACCI L，SAMBRI A，MEDELLIN MR，et al. A new computerized tomography classification to evaluate response to Denosumab in giant cell tumors in the extremities[J]. Acta Orthop Traumato，2019，53(5)：376-380.
[26] RUTKOWSKI P，GASTON L，BORKOWSKA A，et al. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone-multicenter analysis outside clinical trial[J]. EJSO，2018，44(9)：1384-1390.
[27] ZOU C，LIN T，WANG B，et al. Managements of giant cell tumor within the distal radius：a retrospective study of 58 cases from a single center[J]. J Bone Oncol，2019. DOI：10.1016/j.jbo.2018.100211.
[28] 國家药品监督管理局药品审评中心.地舒单抗注射液申请上市技术评审报告[R]. 2019-10.
[29] BIERMANN JS，CHOW W，REED DR，et al. NCCN guidelines insights：bone cancer，version 2：2017[J]. J Natl Compr Canc Netw，2017. DOI：10.6004/jnccn.2017.0017.
(收稿日期：2020-04-29 修回日期：2020-06-18)
(编辑：孙 冰), http://www.100md.com(芮明军 唐文熙 李洪超)